Entry

D10820                      Drug

Name

Olipudase alfa (USAN/INN);
Olipudase alfa (genetical recombination) (JAN);
Xenpozyme (TN)

Formula

C2900H4373N783O791S24

Exact mass

63590.933

Mol weight

63631.0831

Sequence

HPLSPQGHPA RLHRIVPRLR DVFGWGNLTC PICKGLFTAI NLGLKKEPNV ARVGSVAIKL
CNLLKIAPPA VCQSIVHLFE DDMVEVWRRS VLSPSEACGL LLGSTCGHWD IFSSWNISLP
TVPKPPPKPP SPPAPGAPVS RILFLTDLHW DHDYLEGTDP DCADPLCCRR GSGLPPASRP
GAGYWGEYSK CDLPLRTLES LLSGLGPAGP FDMVYWTGDI PAHDVWHQTR QDQLRALTTV
TALVRKFLGP VPVYPAVGNH ESTPVNSFPP PFIEGNHSSR WLYEAMAKAW EPWLPAEALR
TLRIGGFYAL SPYPGLRLIS LNMNFCSREN FWLLINSTDP AGQLQWLVGE LQAAEDRGDK
VHIIGHIPPG HCLKSWSWNY YRIVARYENT LAAQFFGHTH VDEFEVFYDE ETLSRPLAVA
FLAPSATTYI GLNPGYRVYQ IDGNYSGSSH VVLDHETYIL NLTQANIPGA IPHWQLLYRA
RETYGLPNTL PTAWHNLVYR MRGDMQLFQT FWFLYHKGHP PSEPCGTPCR LATLCAQLSA
RADSPALCRH LMPDGSLPEA QSLWPRPLFC
(Disulfide bridge: 43-119, 46-111, 74-85, 175-180, 181-204, 339-385, 538-542, 548-561)

Type

Peptide

Remark

Therapeutic category:

3959

Product:

D10820<JP>

Efficacy

Lysosomal storage disease treatment, Enzyme replacement (acid sphingomyelinase)

Disease

Acid sphingomyelinase deficiency [DS:H00137]

Comment

Enzyme replacement therapy product
Treatment of Niemann-Pick disease type A/B

Target

SMPD1* [HSA_VAR:6609v1] [HSA:6609] [KO:K12350]

Pathway

hsa00600

Sphingolipid metabolism

hsa04071

Sphingolipid signaling pathway

hsa04142

Lysosome

Interaction

Brite

Therapeutic category of drugs in Japan [BR:br08301]
3  Agents affecting metabolism
  39  Other agents affecting metabolism
   395  Enzyme preparations
    3959  Others
     D10820  Olipudase alfa (USAN/INN); Olipudase alfa (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Enzymes
  Hydrolases (EC3)
   Phosphodiesterases
    SMPD1* [HSA_VAR:6609v1]
     D10820  Olipudase alfa (USAN/INN) <JP>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D10820
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D10820
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D10820
Pharmacogenomic biomarkers [br08341.html]
Germline mutations in genetic disorder treatments
  D10820

Other DBs

CAS:	927883-84-9

PubChem:

319902620